Biobypass

(redirected from AdGVVEGF121.10)

Biobypass

A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow—e.g., in patients with CAD and peripheral vascular disease.

Biobypass®

Cardiology A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow–eg, in Pts with CAD and and peripheral vascular disease. See Angiogenesis.
References in periodicals archive ?
GenVec's presentation, "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Pilot Study of the Safety and Feasibility of AdgvVEGF121.
The company's lead investigational compound, AdGVVEGF121.
announced that initial findings obtained from a Phase I clinical trial being conducted at the New York Hospital-Cornell Medical Center to evaluate the safety of its lead investigational compound, AdGVVEGF121.